FDA gives Alembic OK for generic DilacorGeneric Dilacor is indicated for the treatment of hypertension and the management of chronic stable angina. Alvotech, Teva obtain FDA nod for new Selarsdi indicationThe FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include treatment of adults with Crohn’s disease and ulcerative colitis. Natco Pharma’s partner Mylan settles Ozempic patent dispute The terms of the agreement remain confidential. Amneal obtains FDA OK for pyridostigmine bromide ER tablets Pyridostigmine bromide ER is a once-daily soman nerve agent pretreatment pyridostigmine product for the U.S. armed services and U.S. allies. Teva, mAbxience expand partnership for additional oncology biosimilar candidate The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States. Samsung Bioepis releases 2024 U.S. biosimilar market report This year’s Q4 report reflects tocilizumab’s market share and wholesale acquisition cost trend analysis after biosimilars launched in Q2. ANI intros generic Nizoral Ketoconazole shampoo, 2%, had a market value of approximately $69.2 million, per July 2024 IQVIA data. Camber intros generic Seroquel Quetiapine tablets are an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar disorder. Amicus Therapeutics settles Galafold patent litigation with Teva Amicus has granted Teva a license to market generic Galafold beginning in January 2037. Apotex launches generic Sprycel Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated. First Previous 6 7 8 9 10 Next Last
